European Genes Found in Ancient Egyptian Mummy in Ireland

The remains of an Egyptian mummy and its
sarcophagus lie within a tomb at Saqqara, south of Cairo. AP
The remains of an Egyptian mummy and its sarcophagus lie within a tomb at Saqqara, south of Cairo. AP
TT

European Genes Found in Ancient Egyptian Mummy in Ireland

The remains of an Egyptian mummy and its
sarcophagus lie within a tomb at Saqqara, south of Cairo. AP
The remains of an Egyptian mummy and its sarcophagus lie within a tomb at Saqqara, south of Cairo. AP

A research team at the University of Manchester's Center for Biomedical Egyptology, managed to unveil further secrets about the life of mummy Takabuti kept at the Ulster Museum, Belfast.

Previous research used CT scans to look into the cause of the mummy’s death, and showed that it was “stabbed with an axe, and not with a knife”, as it was previously thought.

The new research, published in the Journal of Archaeological Science, provides new insights on the life, death, and embalming of Takabuti, based on a proteomic and genomic analysis of 50 milligrams of bone and thigh muscle. The new findings show that the famous mummy “had European genes that originated from the mother.”

The team also examined the mitochondrial DNA (mtDNA), which revealed a group of maternal genes known as “H4a1 haplogroup” that currently dominates in Europe.

The new discovery supports a theory saying that the family of Takabuti’s mother may have originated outside Egypt, as the name of the mother “Tasenirit” engraved on the mummy’s sarcophagus, is not known elsewhere in Egyptian sources. However, her father’s name, Nespare, and his role as a priest of Amun as indicated from Takabuti’s sarcophagus, suggest that she had direct Egyptian ancestry.

The analyzed proteins also indicate protracted leg muscle activity in the hours before death, which suggests that Takabuti tried to escape the attacker who hit her with the axe.

The researchers note that “the mummy lived in Thebes during the turbulent period when the Kushite rulers of Egypt were conducting military campaigns against the Assyrians, and she may have been caught up in one of these conflicts.”

The team also looked into the secrets of Takabuti’s mummification. CT scan results from former studies showed that the embalming reflected changes in practice during the Third Intermediate and Late Periods, where greater attempts were made to make a mummy look more “realistic”, such as the unusual retention of the complete head of natural hair rather than shaving the head or adding hair extensions.

The new study uncovered other secrets with the help of 20–30 mg needle biopsy sample of the packing material inserted during mummification.

The researchers found that the materials used for embalming contained cedar wood shavings. Using radiocarbon dating, they determined that “the mummification took place in the Third Intermediate Period and in keeping with the previously dated hair and the stylistic dating of the coffin that placed it in the 25th Dynasty.”



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”